Cytosurge AG, founded in 2009, is a biotechnology company that manufactures and distributes cutting edge solutions based on its patented FluidFM ® technology. By uniting the best features of microfluidics and force microscopy, Cytosurge provides innovative products and services to shift boundaries in single-cell gene engineering and omics. The Cytosurge vision into the future is to contribute to human wellbeing through advancements in single cell technologies. At the heart of the technology are the hollow FluidFM Probes – the Micropipette, Nanopipette and the Nanosyringe – specifically designed to provide a wide range of unique applications for single-cell manipulation in biology research. Current systems compatible with FluidFM probes include the FluidFM ADD-ON for AFM systems and the standalone semi-automated FluidFM OMNIUM system. Unique benefits of FluidFM technology include, but are not limited to, single cell adhesion measurements with forces >50nN, gentle intranuclear delivery of CRISPR entities for precise gene engineering of single cells, and semi-automated collection of picoliter-scale single-cell biopsies for single cell sampling solutions for (transcript-) omics analysis.